Sign up
Pharma Capital

Humanigen CEO says company is developing drug to make 'the new frontier' in cancer therapy safer

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive Investors the biopharmaceutical company is developing a drug to make 'the new frontier' in cancer therapy safer therapy by developing its antibody to Phase II studies. 

Durrant says Humanigen's focus is on making chimeric antigen receipter T-cell (CAR-T) therapy safer and more effective, that minimizes the requirement to be in a hospital. Durrant says Humanigen's antibody called lenzilumab can block a molecule called GM-CSF, which is the key master switch that leads to brain inflammation, amoung other things. Durrant says Humanigen is excited to begin Phase II studies to test this, and are partnering with leading insitutions to begin clinical trials. Durrant says Humanigen is hoping to begin Phase II this year once the company completes fundraising. 

 

View full HGEN profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.